Avalo Therapeutics (AVTX) Interest Expenses (2014 - 2015)

Avalo Therapeutics (AVTX) has 13 years of Interest Expenses data on file, last reported at $23.8 million in Q1 2026.

• Quarterly Interest Expenses rose 39566.67% year-over-year to $23.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.8 million (up 10070.94% YoY) and the FY2025 annual result came in at $39.9 million, down 39.23% from the prior year.
• Interest Expenses improved to $23.8 million in Q1 2026, from $9000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $23.8 million in Q1 2026 to a low of -$1.7 million in Q4 2023.
• A 5-year average of $2.1 million and a median of $117000.0 in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses sank 351.7% — and 2026, when it jumped 39566.67%.
• Tracing AVTX's Interest Expenses over 5 years: stood at $675000.0 in 2022, then slumped by 351.7% to -$1.7 million in 2023, then jumped by 103.53% to $60000.0 in 2024, then plunged by 85.0% to $9000.0 in 2025, then jumped by 264344.44% to $23.8 million in 2026.
• The last three Interest Expenses figures came in at $23.8 million (Q1 2026), $9000.0 (Q4 2025), and $59000.0 (Q3 2025), per Business Quant data.